Matrix metalloproteinase-9,-10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis

被引:107
作者
Lorente, Leonardo [1 ]
Martin, Maria M. [2 ]
Labarta, Lorenzo [3 ]
Diaz, Cesar [4 ]
Sole-Violan, Jordi [5 ]
Blanquer, Jose [6 ]
Orbe, Josune [7 ]
Rodriguez, Jose A. [7 ]
Jimenez, Alejandro [8 ]
Borreguero-Leon, Juan M. [9 ]
Belmonte, Felipe [2 ]
Medina, Juan C. [2 ]
LLiminana, Maria C. [10 ]
Ferrer-Agueero, Jose M. [5 ]
Ferreres, Jose [6 ]
Mora, Maria L. [1 ]
Lubillo, Santiago [2 ]
Sanchez, Manuel
Barrios, Ysamar [8 ]
Sierra, Antonio [11 ]
Paramo, Jose A. [7 ]
机构
[1] Hosp Univ Canarias, Intens Care Unit, San Cristobal la Laguna 38320, Spain
[2] Hosp Univ Nuestra Senora Candelaria, Intens Care Unit, Santa Cruz de Tenerife 38010, Spain
[3] Hosp San Jorge Huesca, Intens Care Unit, Huesca 22004, Spain
[4] Hosp Insular, Intens Care Unit, Las Palmas Gran Canaria 35016, Spain
[5] Hosp Univ Dr Negrin, Intens Care Unit, Las Palmas Gran Canaria 35010, Spain
[6] Hosp Clin Univ Valencia, Intens Care Unit, Valencia 46004, Spain
[7] Univ Navarra, CIMA, Atherosclerosis Res Lab, Pamplona 31008, Spain
[8] Hosp Univ Canarias, Res Unit, San Cristobal la Laguna 38320, Spain
[9] Hosp Univ Canarias, Dept Lab, San Cristobal la Laguna 38320, Spain
[10] Hosp San Jorge Huesca, Dept Lab, Huesca 22004, Spain
[11] Hosp Univ Canarias, Dept Microbiol, San Cristobal la Laguna 38320, Spain
来源
CRITICAL CARE | 2009年 / 13卷 / 05期
关键词
GELATINASE-B; LUNG INJURY; IN-VITRO; MATRIX-METALLOPROTEINASE-9; COLLAGENASE; ENDOTOXIN; ACTIVATION; EXPRESSION; LACTATE; PATHWAY;
D O I
10.1186/cc8115
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Introduction Matrix metalloproteinases ( MMPs) play a role in infectious diseases through extracellular matrix (ECM) degradation, which favors the migration of immune cells from the bloodstream to sites of inflammation. Although higher levels of MMP-9 and tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) have been found in small series of patients with sepsis, MMP-10 levels have not been studied in this setting. The objective of this study was to determine the predictive value of MMP-9, MMP-10, and TIMP-1 on clinical severity and mortality in a large series of patients with severe sepsis. Methods This was a multicenter, observational, and prospective study carried out in six Spanish Intensive Care Units. We included 192 (125 surviving and 67 nonsurviving) patients with severe sepsis and 50 age- and sex-matched healthy controls in the study. Serum levels of MMP-9, MMP-10, TIMP-1, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-10 were measured in patients with severe sepsis at the time of diagnosis and in healthy controls. Results Sepsis patients had higher levels of MMP-10 and TIMP-1, higher MMP-10/TIMP-1 ratios, and lower MMP-9/TIMP-1 ratios than did healthy controls (P < 0.001). An association was found between MMP-9, MMP-10, TIMP-1, and MMP-9/TIMP-1 ratios and parameters of sepsis severity, assessed by the SOFA score, the APACHE-II score, lactic acid, platelet count, and markers of coagulopathy. Nonsurviving sepsis patients had lower levels of MMP-9 (P = 0.037), higher levels of TIMP-1 (P < 0.001), lower MMP-9/TIMP-1 ratio (P = 0.003), higher levels of IL-10 (P < 0.001), and lower TNF-alpha/IL-10 ratio than did surviving patients. An association was found between MMP-9, MMP-10, and TIMP-1 levels, and TNF-alpha and IL-10 levels. The risk of death in sepsis patients with TIMP-1 values greater than 531 ng/ml was 80% higher than that in patients with lower values (RR = 1.80; 95% CI = 1.13 to 2.87; P = 0.01; sensitivity = 0.73; specificity = 0.45). Conclusions The novel findings of our study on patients with severe sepsis (to our knowledge, the largest series reporting data about MMP levels in sepsis) are that reduced MMP-9/TIMP-1 ratios and increased MMP-10 levels may be of great pathophysiologic significance in terms of severity and mortality, and that TIMP-1 levels may represent a biomarker to predict the clinical outcome of patients with sepsis.
引用
收藏
页数:9
相关论文
共 49 条
[1]   Differential release of matrix metalloproteinase-9 and nitric oxide following infusion of endotoxin to human volunteers [J].
Albert, J ;
Radomski, A ;
Soop, A ;
Sollevi, A ;
Frostell, C ;
Radomski, MW .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2003, 47 (04) :407-410
[2]   Divergent associations of tissue inhibitors of metalloproteinases-1 and -2 with the prothrombotic/fibrinolytic state [J].
Aznaouridis, Konstantinos ;
Vlachopoulos, Charalambos ;
Dima, Ioanna ;
Vasiliadou, Carmen ;
Ioakeimidis, Nikolaos ;
Baou, Katerina ;
Stefanadi, Elli ;
Stefanadis, Christodoulos .
ATHEROSCLEROSIS, 2007, 195 (01) :212-215
[3]  
Belaaouaj AA, 2000, J BIOL CHEM, V275, P27123
[4]   MATRIX METALLOPROTEINASES - A REVIEW [J].
BIRKEDALHANSEN, H ;
MOORE, WGI ;
BODDEN, MK ;
WINDSOR, LJ ;
BIRKEDALHANSEN, B ;
DECARLO, A ;
ENGLER, JA .
CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE, 1993, 4 (02) :197-250
[5]   PROLONGED ACTIVATION OF JUN AND COLLAGENASE GENES BY TUMOR NECROSIS FACTOR-ALPHA [J].
BRENNER, DA ;
OHARA, M ;
ANGEL, P ;
CHOJKIER, M ;
KARIN, M .
NATURE, 1989, 337 (6208) :661-663
[6]   Timeline - Matrix metalloproteinases: a tail of a frog that became a prince [J].
Brinckerhoff, CE ;
Matrisian, LM .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (03) :207-214
[7]  
CORCORAN ML, 1992, J BIOL CHEM, V267, P515
[8]  
Dubois B, 2002, EUR J IMMUNOL, V32, P2163, DOI 10.1002/1521-4141(200208)32:8<2163::AID-IMMU2163>3.0.CO
[9]  
2-Q
[10]  
Elkington PTG, 2005, CLIN EXP IMMUNOL, V142, P12, DOI [10.1111/j.1365-2249.2005.02840.x, 10.1111/j.1365-2249.2005.02840.X]